Mei Pharma, INC

Lite Strategy, Inc. announced the repurchase of 13% of its outstanding shares since December 2025, funded by treasury operations, thereby increasing the amount of Litecoin held per share.

Lite Strategy, Inc. presented investor materials on July 24, 2026, detailing its strategy to institutionalize Litecoin as a treasury asset, highlighting its first-mover advantage, substantial Litecoin holdings, active treasury management, and a $25M share repurchase program.

Lite Strategy, Inc. announced its fiscal 2026 third quarter results, highlighting $0.7 million in proceeds from its covered call program and the repurchase of 1,629,136 shares.

Lite Strategy, Inc. announced strong fiscal Q2 2026 results, driven by successful Litecoin covered call options generating $600,000 and the launch of a $25 million stock repurchase program.

Lite Strategy, Inc. stockholders approved the 2026 Omnibus Equity Compensation Plan and elected two directors at the annual meeting.

Lite Strategy, Inc. has formalized the employment agreement for Justin J. File, confirming his roles as CEO, CFO, and Secretary with a $575,000 base salary and comprehensive severance package.

Lite Strategy Inc. reports significant shift towards digital asset treasury strategy, with substantial digital asset holdings and related income/losses impacting financial results.

Lite Strategy, Inc. shifts focus from pharmaceuticals to a Litecoin treasury strategy, reporting a significant net loss in its latest quarterly filing.

Lite Strategy, Inc. shifted its primary strategy to include Litecoin as a reserve asset, reporting a significantly reduced net loss for the quarter ended September 30, 2025.

MEI Pharma announces Q3 2025 results, highlighting a strategic shift towards evaluating strategic alternatives, including a potential wind-down, and the sale of ME-344.

MEI Pharma announces Q2 2025 financial results amid strategic shift, including the sale of ME-344 and discontinuation of voruciclib clinical development.

MEI Pharma reports its Q1 2025 financial results, highlighting a significant revenue decrease due to the termination of a key collaboration agreement, alongside strategic shifts including a reduction in force and the sale of a key asset.

Lite Strategy, Inc., formerly MEI Pharma, has completed a $100 million PIPE and fully deployed proceeds into a Litecoin Treasury Strategy, marking a significant shift from its pharmaceutical development focus.

MEI Pharma is evaluating strategic options, including a potential wind-down, after discontinuing the clinical development of voruciclib.

Lite Strategy, Inc. Director James P. Flynn acquired 25,000 common shares for $0.8555 per share, increasing his beneficial ownership.

Lite Strategy's CEO, CFO, and Secretary, Justin J. File, was granted 455,000 stock options as employment compensation, vesting over 34 months.

Alexander Schornstein, a director and former 10% owner of Lite Strategy, Inc., sold 690,611 shares of common stock for approximately $1.37 per share.

Lite Strategy, Inc. Director James P Flynn acquired 70,000 shares of common stock at an average price of $1.3957 per share.

Lite Strategy, Inc.'s CEO, Justin J. File, filed an amended Form 4 to correct the number of stock options granted, now accurately reporting 180,000 options.

Lite Strategy Director James P. Flynn acquired 12,100 shares of common stock in a pre-planned transaction.

Lite Strategy, Inc. announced a supplement to its proxy statement, confirming Board member Joshua Riezman's independence, increasing the total independent directors to four out of six.

LITE STRATEGY, INC. has filed a Definitive Proxy Statement with the SEC.

Lite Strategy, Inc. announces its virtual 2026 Annual Meeting of Stockholders to vote on director elections, executive compensation, auditor ratification, and a new equity compensation plan.

MEI Pharma will hold its annual stockholder meeting virtually on January 30, 2025, to vote on director elections, executive compensation, and auditor ratification.

MEI Pharma will hold its annual stockholder meeting virtually on January 30, 2025, to elect directors, approve executive compensation, and ratify the appointment of auditors.

A group of activist investors, including Funicular Funds and Anson Funds, has terminated their cooperation agreement with MEI Pharma, Inc. and seen their board representative resign after their collective beneficial ownership fell below 5% due to a recent private placement.

Alexander Schornstein has divested all shares in Lite Strategy, Inc., reporting 0% beneficial ownership as of June 30, 2026.

Alexander Schornstein has filed an amended Schedule 13G, reporting a 9.99% beneficial ownership stake in Lite Strategy, Inc.

The Vanguard Group has filed an amended Schedule 13G, reporting a 2% passive beneficial ownership stake in Lite Strategy Inc as of September 30, 2025.

Alexander Schornstein has increased his beneficial ownership in MEI Pharma, Inc. to 13.29% of common stock, coinciding with the company's rebranding to Lite Strategy, Inc.

Alexander Schornstein has reported a 6.53% beneficial ownership stake in MEI Pharma, Inc., totaling 2,115,000 shares of common stock.

Citadel entities, including Kenneth Griffin, have disclosed a combined beneficial ownership of 9.99% in MEI Pharma, Inc., totaling 3,245,888 shares.